NEW YORK – Bionano Genomics reported a 33 percent year-over-year decrease in third quarter revenues after the close of the market on Thursday, driven by a change in revenue mix between instrument sales and the firm's reagent rental program.
"We saw continued adoption by cytogenomic labs around the world and for COVID host genome research, publication of several major studies on cancer genomics, genetic diseases, and reference genome assembly, and made significant improvements to the Saphyr system," Bionano Genomics CEO Erik Holmlin said in a statement.